Office life at Atrium.

News Releases


Atrium appoints Peter Laidlaw as Active Underwriter

Atrium Underwriters Limited (Atrium), the managing agent for Lloyd’s Syndicate 609, today announced that Peter Laidlaw has been appointed Active Underwriter effective 1st January 2023. This appointment is part of a management restructure that will see existing Active Underwriter, Toby Drysdale, take on an advisory role as Director of Corporate Underwriting Review with responsibility for consulting the Board and providing underwriting review services to the Group.

Richard Harries, CEO at Atrium Underwriters, commented: “I am delighted that Peter has accepted the role of Active Underwriter of Atrium Syndicate 609. This move comes as part of our long-term succession plan and with over 29 years at Atrium, Peter has long been the standout candidate to take over from Toby. Toby has been an exceptional Active Underwriter and we at Atrium, our Names and Shareholders owe him a huge debt of gratitude. I’m pleased that Toby has agreed to stay on and support the business and we’re very fortunate he has agreed to do so.”

Toby Drysdale, Active Underwriter, Atrium followed: “It has been a privilege to have been the Active Underwriter of Syndicate 609 for the last 7 years. After much consideration I have decided to step down for personal reasons. Atrium is a very special company, and I am delighted that it's approach to flexible working will allow me to continue to contribute to its success whilst achieving a better work/life balance.”

Peter Laidlaw, Senior Underwriter, Atrium added: “Having spent my entire career at Atrium, I am honoured to take on the leadership of such an exceptional team of underwriters. It has been a privilege to work closely with Toby over the years and I am delighted that I will continue to have access to his wisdom and to have his ongoing support. I am excited about both Atrium's future and the opportunities that lie ahead.”

All proposed changes to senior management functions, roles and responsibilities are subject to regulatory discussion and to any/all relevant regulatory approvals.